ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Amicus' Pompe disease therapy joins early access scheme pharmatimes
June 10, 2021Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics' cipaglucosidase alfa with miglustat was approved for the UK's ...
Pharma Sources Insight January 2025
